Navigation Links
Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
Date:9/19/2011

NEW YORK, Sept. 19, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that management will present at the JMP Securities Healthcare Conference on Wednesday, September 28, 2011 at 11:00 A.M. ET in New York, NY.  David McDonald, Chief Financial Officer, will provide an overview of the Company's business strategy and recent corporate developments.

Attendance at this conference is by invitation only.  Delcath will offer a live webcast and subsequent archived replay of its presentation, which may be accessed at http://www.delcath.com/investors/events/.

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to di
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Report Details  New study shows ... What does the future hold for top companies ... new report shows you potential revenues to 2025, assessing ... 242-page report provides 185 tables, charts, and graphs. Discover ... future market prospects. Our new study lets you assess ...
(Date:3/27/2015)... -- According to a new market research ... Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices (Mapping, ... - Global Forecasts to 2019 ", published by MarketsandMarkets, the ... Billion by 2019 with a CAGR of around 10.3% ... Browse   90   ma rket data ...
(Date:3/27/2015)... March 27, 2015 The International Myeloma Foundation ... patients while working toward prevention and a cure – ... introducing a federal resolution (H. Res. 174) that supports ... "National Multiple Myeloma Awareness Month." Currently there ... and more than 110,000 new cases are diagnosed yearly, ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... N.J., Jan. 25, 2012  Covance Inc. (NYSE: ... has authorized the repurchase of up to $300 million ... addition to the approximately 800,000 shares remaining under a ... of the Company,s common stock. Any purchases under this ...
... 2012 Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, today announced ... year 2011 on Wednesday, February 8. The ... financial results and operating activities, open to all interested ...
Cached Medicine Technology:Covance Board Authorizes $300 Million Stock Buyback 2Thoratec Schedules Fourth Quarter Conference Call, Webcast 2
(Date:3/27/2015)... 2015 The 2015 Deep Market ... professional and in-depth study on the current state ... a focus on the Chinese situation. , The ... including definitions, classifications, applications and industry chain structure. ... the international and Chinese domestic situations including development ...
(Date:3/27/2015)... March 27, 2015 Airy Jeanine is ... the official music video for her debut song “Mama’s ... Combining live-action and abstract styling effects, the thematic video ... on YouTube, Vimeo, and assorted outlets. It will be ... of an expanding full-scale marketing strategy. The video promotion ...
(Date:3/27/2015)... 27, 2015 Smile Brands Inc. ( ... business support services to dental groups in the United ... affiliated Castle Dental office in Hendersonville, TN. ... 37075, this new Castle Dental office provides families with ... latest in comprehensive, quality dental care. Hendersonville marks the ...
(Date:3/27/2015)... “ VXi BlueParott Reveal ” was ... Report, which features the latest and coolest technology products ... special reporter for NewsWatch, conducted the review and shared ... eliminating 90% of ambient noise. , Today, business is ... are important to any professional, voice calls are just ...
(Date:3/27/2015)... March 27, 2015 The Florida Center ... Brain Cancer Cure (ABC2), awarded $350,000 to support brain ... Florida, The Scripps Research Institute and H. Lee Moffitt ... studies with a clear development path and potential to ... the near future. , The awards fund research ...
Breaking Medicine News(10 mins):Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3Health News:Airy Jeanine Releases ‘’Mama’s Girl” Official Music Video 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 3Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 2Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 3
... , , , ... 100 mg showed clear advantages over Crinone* (progesterone gel) for ... (PK) study. Progesterone is necessary to increase endometrial receptivity ... , , ENDOMETRIN(R) rapidly reached ...
... , , CHICAGO, Aug. ... ADLS), today announced positive results from an animal study involving ... to measure Restanza,s therapeutic efficacy in treating inhalation anthrax after ... non-human primate study showed that a 14-day course of Restanza ...
... , FRANKLIN, Mass., Aug. 31 PLC Systems Inc. ... vascular medical device-based technologies, today announced that it will demonstrate its ... European Society of Cardiology, August 29 - September 2, 2009 in ... to attend this event. , , ...
... , OAKLAND, Calif., Aug. 31 Life ... that keep mind, body and emotions rigid. Especially during stressful ... is a challenge. The Breema Bodywork Method helps people find ... regardless of what challenges they may be facing. To help ...
... BEIJING, Aug. 31 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:, ... China, announced,today that Sinovac,s H1N1 vaccine has passed the experts ... vaccine is expected to,obtain the production license within this week. ... 2009, State Food and Drug Administration (SFDA),organized and held an ...
... , DEERFIELD, Ill., Aug. 31 Chicago-based Lundbeck ... Achievement by the Illinois Chapter of the Huntington,s Disease Society of ... (HD) community and making a meaningful contribution to the lives of ... past Friday at the fifth annual Celebration of Hope ...
Cached Medicine News:Health News:Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN(R) Over Crinone(R) for Progesterone Supplementation 2Health News:Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN(R) Over Crinone(R) for Progesterone Supplementation 3Health News:Advanced Life Sciences' Restanza Demonstrates Efficacy in Treating Anthrax Infection 2Health News:Advanced Life Sciences' Restanza Demonstrates Efficacy in Treating Anthrax Infection 3Health News:Advanced Life Sciences' Restanza Demonstrates Efficacy in Treating Anthrax Infection 4Health News:Advanced Life Sciences' Restanza Demonstrates Efficacy in Treating Anthrax Infection 5Health News:PLC Medical Systems to Demonstrate RenalGuard(R) at ESC 2009 2Health News:PLC Medical Systems to Demonstrate RenalGuard(R) at ESC 2009 3Health News:PLC Medical Systems to Demonstrate RenalGuard(R) at ESC 2009 4Health News:The Breema Center Presents Its Fall Week-Long Intensive on Giving and Receiving Breema Bodywork 2Health News:Sinovac's H1N1 Vaccine Passes Experts Evaluation Organized by SFDA 2Health News:Sinovac's H1N1 Vaccine Passes Experts Evaluation Organized by SFDA 3Health News:Lundbeck Inc. Recognized With Award of Excellence in Corporate Achievement for Its Commitment to Huntington's Disease Community 2Health News:Lundbeck Inc. Recognized With Award of Excellence in Corporate Achievement for Its Commitment to Huntington's Disease Community 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: